Upsized $14M Placement Extends Runway Post IA
Filed with ASX · · 44 pages · English and French
Summary by 6ix AI
Paradigm Biopharmaceuticals Ltd. has announced the successful completion of a capital raise through a placement and a share purchase plan to extend its financial runway for ongoing clinical trials. The placement raised a significant amount, exceeding initial targets due to strong investor demand, while the share purchase plan allows eligible shareholders to participate under similar terms. This announcement highlights the company's strategy to reduce reliance on existing convertible note facilities and prepare for upcoming key data milestones.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm Achieves 50% Patient Dosing in Phase 3
- Appendix 4D and Half Year Report
- Drawdown of Tranche 3 under the Convertible Note Facility
- Published Canine Study Strengthens iPPS Phase 3 Rationale
- Oral OA Animal Therapy Progresses via AVet Deal
Later from Paradigm Biopharmaceuticals
- March 2026 Quarterly Activities Report & Appendix 4C
- DSMB 20% Review Supports Phase 3, Moldova Activated
- Results of Share Purchase Plan
- PAR Completes Enrolment in Pivotal Phase 3
- Drawdown of Tranche 4 under the Convertible Note Facility
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals